Page last updated: 2024-09-05

sb 203580 and Lymphoma, AIDS-Related

sb 203580 has been researched along with Lymphoma, AIDS-Related in 1 studies

Research

Studies (1)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	0 (0.00)	18.2507
2000's	1 (100.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Bonavida, B; Garban, H; Huerta-Yepez, S; Jazirehi, AR; Vega, MI	1

Other Studies

1 other study(ies) available for sb 203580 and Lymphoma, AIDS-Related

Article	Year
Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis. Oncogene, 2005, Dec-08, Volume: 24, Issue:55 Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyridines; Rituximab; Transcription, Genetic	2005

Article

Year

Rituximab (chimeric anti-CD20) sensitizes B-NHL cell lines to Fas-induced apoptosis.

Oncogene, 2005, Dec-08, Volume: 24, Issue:55

Topics: Antibodies, Monoclonal; Antibodies, Monoclonal, Murine-Derived; Antigens, CD20; Antineoplastic Agents; Apoptosis; Burkitt Lymphoma; Cell Line, Tumor; Cell Survival; Enzyme Inhibitors; fas Receptor; Gene Expression Regulation, Neoplastic; Humans; Imidazoles; Lymphoma, AIDS-Related; Lymphoma, B-Cell; NF-kappa B; p38 Mitogen-Activated Protein Kinases; Pyridines; Rituximab; Transcription, Genetic

2005